(Waltham, MA – July 22, 2015) RESOLVE New England (RNE), the region’s infertility support, education, and advocacy organization, is proud to announce a new partnership with Nora Therapeutics, Inc., a biotechnology company focused on developing therapeutics to address significant unmet needs in reproductive medicine. The RNE and Nora partnership focuses on the organizations’ shared goals of raising awareness of miscarriage and connecting people to much needed resources.
“Providing education for individuals and couples struggling to become parents is one of the three pillars of our RNE mission,” said Kate Weldon LeBlanc, Executive Director of RESOLVE New England. “With support from and collaboration with Nora Therapeutics, we look forward to improving access to information about pregnancy loss, as we know that unfortunately many in our community are suffering.” The partnership has enabled RNE to add a new section of the website focused on miscarriage, which recently launched. The web-based information aligns well with the existing RNE support group for those who have experienced pregnancy loss.
“Nora Therapeutics is proud to join with RESOLVE New England to enhance education resources as it relates to pregnancy loss and recurrent miscarriage,” said Chris McClain, Co-Founder of Nora Therapeutics. “Miscarriage remains in the shadows in many ways, so we are committed to helping to raise awareness and bring critical information to those who desperately need it.”
About RESOLVE New England
RESOLVE New England is a non-profit, consumer-based infertility support organization that provides compassionate and informed help to people experiencing infertility and seeking to build families. allpathsfb.org
About Nora Therapeutics
Nora Therapeutics is a privately held biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine. Nora’s lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may reduce the risk of miscarriage by optimizing maternal-fetal immune tolerance. NT100 is being studied in a Phase 2 randomized, double-blind, placebo controlled trial (RESPONSE) in women with a history of unexplained recurrent miscarriage. For more information, please visit our website at noratherapeutics.com.
MEDIA CONTACTS:
Nora Therapeutics, Inc.
pr@noratherapeutics.com
RESOLVE New England
Kate Weldon LeBlanc, Executive Director
781.890.2250
kwleblanc@allpathsfb.org